MK 1966

Drug Profile

MK 1966

Alternative Names: MK-1966

Latest Information Update: 19 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Merck & Co
  • Class Antineoplastics; Immunotherapies
  • Mechanism of Action Immunomodulators; Interleukin 10 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Haematological malignancies

Most Recent Events

  • 01 Jun 2016 Phase-I clinical trials in Haematological malignancies (Combination therapy; Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT02731742)
  • 01 Jun 2015 Dynavax Technologies and Merck agree to co-develop SD 101 and MK 1966 for Haematological malignancies
  • 01 Jun 2015 Preclinical trials in Haematological malignancies in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top